Towards Healthcare

Gene Overexpression Cell Line Construction Service Manufacturers and Development Strategy

Date : 15 October 2025

Top Innovators in the Market and Market Growth

Gene Overexpression Cell Line Construction Service Market Companies

Market Growth

The global gene overexpression cell line construction service market size is calculated at US$ 788.63 million in 2024, grew to US$ 848.01 million in 2025, and is projected to reach around US$ 1,629.93 million by 2034. The market is expanding at a CAGR of 7.53% between 2025 and 2034.

The funding and investments from government organizations foster innovative therapies to cure various diseases. For instance, in July 2025, the Australian Government, the Department of Health, Disability, and Aging, invested $50 million to accelerate genomics research that will introduce personalized treatments for several diseases through funding from the Medical Research Future Fund (MRFF).

  • In July 2025, MedGenome raised $47.5 million in its Series E funding, which was supported by Maj Invest and Novo Holdings for the expansion of its genomics offerings in India.

Value Chain Analysis

R&D

The R&D process for gene overexpression cell line construction service includes gene synthesis, vector construction, transfection/transduction, stable selection, clone isolation and expansion, validation, and characterization.

Key Players: Creative Biogene, Cyagen, Sino Biological, VectorBuilder, System Biosciences, and AcceGen.

Clinical Trials and Regulatory Approvals

The clinical trials involve the increased focus on safety, continued growth in trials and funding, and the use of real-world evidence. The regulatory approvals are given for therapies like Elevidys, Rytelo, Amtagvi, and Lenmeldy.

Key Players: Thermo Fisher Scientific Inc., Lonza, Catalent, WuXi AppTec, Charles River Laboratories, AGC Biologics.

Patient Support and Services

These services include initial consultation, customized strategy design, vector design and construction, quality control and testing, regular progress reporting, technical support, documentation, etc.

Key Players: Creative Biogene, Creative Biolabs, Creative Bioarray, Cyagen, System Biosciences.

Latest Announcements by Industry Leaders

In January 2025, Norman Schwartz, CEO of Bio-Rad Laboratories, proclaimed that Bio-Rad Laboratories will remain prominent in clinical diagnostics and digital biology to advance science and improve lives through improved healthcare outcomes. Geneoscopy’s ColoSense screening test is introduced for use with the QXDx ddPCR platform of Bio-Rad and offers an efficient detection of colorectal cancer and advanced adenomas. Bio-Rad will support Geneoscopy’s R&D and commercialization efforts and advance Bio-Rad’s droplet digital PCR platform for oncology applications across translational research and clinical diagnostics. 

Recent Developments in the Market

  • In April 2025, Thermo Fisher Scientific Inc. brought an enhanced platform technology into action and a new CHO K-1 cell line that requires less time to investigational new drug filings, from 13 to 9 months. This enhancement will assist biotechnology and pharmaceutical companies in overcoming logistics challenges within pre-clinical biologic drug development. 
  • In February 2024, GenScript Biotech announced the launch of its GenScript Life Science Research Grant Program that will encourage advancements in science and innovations across vaccine development, gene and cell therapy development, antibody drug discovery, plant sciences research, and diagnostic development.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com